Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Molecular genetics and metabolism

Topics

Medicine

Neuroscience

Clinical Trials

Epidemiology

Physiology

Show all topics

DOI

10.1016/j.ymgme.2022.11.002

License

CC-BY

Other Formats

PDF